[01] Manal Omran Taryam, Primary Health Care Services Sector, Dubai Health Authority, Dubai, UAE. [02] Waleed Al Faisal, Health Affairs Department, Primary Health Care Services Sector, Dubai Health Authority, Dubai, UAE. [03] Hamid Hussein, Health Affairs Department, Primary Health Care Services Sector, Dubai Health Authority, Dubai, UAE. [04] Eldaw Suliman, Dubai Health Authority, Dubai, UAE. [05] Tariq Al Janahi T., Dubai Statistics Center, Dubai, UAE. [06] Ali Al Salaq, Dubai Statistics Center, Dubai, UAE. [07] Ahmed Wasfy, Dubai Health Authority, Dubai, UAE.

High Blood pressure affects more than a quarter of the global adult population. It is projected in year 2025 to increase by 24% in developed countries and 80% in developing countries. The increase is expected to be much higher than these projections. National surveys of prevalence, awareness, treatment, and control provide basis for assessing the burden of hypertension in the community. This study aims to determine prevalence of high blood pressure among different population segments of Dubai population and the patterns of distributions. Dubai Household Health Survey was conducted in 2014 as a Cross-sectional, multistage, stratified, Cluster survey. Houses were visited to obtain detailed information on the different health-related issues. High Blood pressure affects more than a quarter of the global adult population. It is projected in year 2025 to increase by 24% in developed countries and 80% in developing countries. The increase is expected to be much higher than these projections. National surveys of prevalence, awareness, treatment, Data were entered to the computer using Excel sheet and analyzed using SPSS 21. The study showed that about 2.5% of males, 2.8 of female, and 2.5% of the total in the age group 18-59 years are diagnosed as hypertensive. When combined with elderly, 3.2% of males, 5.1% of females and 3.5% of the total are diagnosed as hypertensive. When it comes to nationality, the study showed that about 18.9% of total Emirati have diagnosed as hypertensive, 20.0% of males and 18.0% of females. Almost one quarter of Dubai Emirati population have been diagnosed as having high blood pressure. One in each four individuals are hypertensive. This greatly puts them at risk of developing cardiovascular morbidity and mortality at long term. National screening, national registry, awareness, population-based interventions, policies and legislations are needed to be addressed as top priority.

Hypertension, Prevalence and Patterns, Dubai Population

[01] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. The Lancet. 2005; 365(9455): 217–223. [02] Tu K, Chen Z, Lipscombe L. Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. The Canadian Medical Association Journal. 2008; 178(11): 1429–1435. [03] Al-Nozha M, Abdullah M, Arafah MR, et al. Hypertension in Saudi Arabia. Saudi Medical Journal.2007; 28(1): 77–84. [04] Costanzo S, Di Castelnuovo A, Zito F, et al. Prevalence, awareness, treatment and control of hypertension in healthy unrelated male-female pairs of European regions: the dietary habit profile in European communities with different risk of myocardial infarction—the impact of migration as a model of gene-environment interaction project. Journal of Hypertension. 2008; 26(12): 2303–2311. [05] Ibrahim M, Rizk H, Appel L, et al. Hypertension prevalence, awareness, treatment, and control in Egypt. Results from the Egyptian National Hypertension Project (NHP) Hypertension. 1995; 26(6): 886–890. [06] Harington M, Kincaid-Smith P, Mc Michael J. Results of treatment in malignant hypertension: a seven-year experience in 94 cases. BMJ. 1959; 2: 969–980. [07] Yu SH, Whitworth JA, Kincaid-Smith PS. Malignant hypertension: aetiology and outcome in 83 patients. Clin Exp Hypertens A. 1986; 8: 1211–1230. [08] Mohler ER, Freis ED. Five-year survival of patients with malignant hypertension treated with antihypertensive agents. Am Heart J. 1960; 60: 329–335. [09] Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: comparing contributions from primary prevention and secondary prevention. BMJ. 2005; 331: 614. [10] Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269–1276. [11] Rodgers A, Lawes C, MacMahon S. Reducing the global burden of blood pressure related cardiovascular disease. J Hypertens 2000; 18(Suppl 1): S3–S6. [12] Dubai Statistics Center. Population Bulletin, Emirate of Dubai, 2014. Available from: https://www.dsc.gov.ae/Publication/Population%20Bulletin%20Emirate%20of%20Dubai%202014.pdf Accessed on Tuesday 13 December 2016. [13] R Gupta. Trends in hypertension epidemiology in India. Journal of Human Hypertension (2004) 18, 73–78. doi:10.1038/sj.jhh.1001633. [14] Abdalla A. Saeed, Nasser A. Al-Hamdan, Ahmed A. Bahnassy, Abdelshakour M. Abdalla, Mostafa A. F. Abbas, and Lamiaa Z. Abuzaid. Prevalence, Awareness, Treatment, and Control of Hypertension among Saudi Adult Population: A National Survey. Int J Hypertens. 2011; 2011: 174135. Published online 2011 Sep 6. doi: 10.4061/2011/174135 PMCID: PMC3168271. [15] Perkovic V, Huxley R, Wu Y, Prabhakaran D, MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension. 2007; 50(6): 991–997. [16] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. The Lancet. 2005; 365(9455): 217–223. [17] Tu K, Chen Z, Lipscombe L. Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. The Canadian Medical Association Journal. 2008; 178(11): 1429–1435. [18] Al-Nozha M, Abdullah M, Arafah MR, et al. Hypertension in Saudi Arabia. Saudi Medical Journal. 2007; 28(1):77–84. [19] Costanzo S, Di Castelnuovo A, Zito F, et al. Prevalence, awareness, treatment and control of hypertension in healthy unrelated male-female pairs of European regions: the dietary habit profile in European communities with different risk of myocardial infarction—the impact of migration as a model of gene-environment interaction project. Journal of Hypertension. 2008; 26(12): 2303–2311. [20] Ibrahim M, Rizk H, Appel L, et al. Hypertension prevalence, awareness, treatment, and control in Egypt. Results from the Egyptian National Hypertension Project (NHP) Hypertension. 1995; 26(6): 886–890. [21] Furberg CD, Wright JT, Jr., Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Journal of the American Medical Association. 2002; 288(23): 2981–2997. [22] Erem C, Hacihasanoglu A, Kocak M, Deger O, Topbas M. Prevalence of prehypertension and hypertension and associated risk factors among Turkish adults: Trabzon Hypertension Study. Journal of Public Health. 2009; 31(1): 47–58. [23] Son PT, Quang NN, Viet NL, et al. Prevalence, awareness, treatment and control of hypertension in Vietnam—results from a national survey. Journal of Human Hypertension. 2011. [24] Pereira M, Azevedo A, Barros H. Determinants of awareness, treatment and control of hypertension in a Portuguese population. Sociedade Portuguesa de Cardiologia. 2010; 29(12): 1779–1792. [25] Arnaout MS, Almahmeed W, Ibrahim M, et al. Hypertension and its management in countries in Africa and the Middle East, with special reference to the place of β-blockade. Current Medical Research and Opinion. 2011; 27(6): 1223–1236. [26] Singh R, Fedacko J, Pella D, et al. Prevalence and risk factors for prehypertension and hypertension in five Indian cities. Acta Cardiologica. 2011; 66(1): 29–37. [27] Pinto E. Blood pressure and ageing. Postgraduate Medical Journal. 2007; 83(976): 109–114.